UMRX -23%/AH* on FDA clinical hold: https://www.globenewswire.com/news-release/2019/07/02/1877594/0/en/Unum-Therapeutics-Announces-Regulatory-Update-from-Phase-1-Trial-with-ACTR087.html *The stock is -30% today cumulatively, including the regular and AH sessions.